GlassScriptPhysician profile
Michael V Robers
NPI 1760892400
$40,762.28
in general payments reported to CMS, 2019-2025
11 companies · $20K in 2025
The $20K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2022: $46.40 · 2023: $6,912 · 2024: $13K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Travel and Lodging: $5,526 · Food and Beverage: $3,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,506.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,425.00 |
| Travel and Lodging | $5,526.34 |
| Food and Beverage | $3,031.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $25,471.76 | 2024-2025 | |
| Genentech USA, INC. | $9,876.78 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Genzyme Corporation | $4,123.45 | 2023-2024 | |
| Biogen, INC. | $537.18 | 2019-2025 | Vumerity, Tysabri |
| Emd Serono, INC. | $308.06 | 2023-2025 | Mavenclad, Mavenclad |
| Novartis Pharmaceuticals Corporation | $160.89 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $130.58 | 2025 | |
| Amgen INC. | $118.23 | 2024 | Uplizna |
| Celgene Corporation | $35.35 | 2025 | Zeposia |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Robers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.